Tricuspid Insufficiency Treatment Market Size & Share, by Disease Type (Tricuspid Regurgitation, Tricuspid Stenosis); End-User (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Laboratories); Surgery Type (Invasive, Minimally Invasive) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3327
  • Published Date: Nov 28, 2023
  • Report Format: PDF, PPT

Companies Dominating the Tricuspid Insufficiency Treatment Landscape

top-features-companies
    • Abbott Laboratories
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Labcor Laboratorios Ltda.
    • LivaNova, plc
    • Sorin S.p.A.
    • Cyberonics, Inc.
    • Hologic, Inc.
    • Corcym UK Limited
    • Intuitive Surgical
    • Sonova Holding AG
    • Hill-Rom Holdings Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • November 2019: LivaNova PLC, a announced it is ending its Caisson Transcatheter Mitral Valve Replacement (TMVR) program and will undertake a restructuring of its heart valve business to improve profitability and ensure business continuity. “The time has come to address the continued declines we have experienced in our heart valve business. We will restructure and simplify our heart valve manufacturing network, which will eliminate operational overlap between facilities and enable us to address new regulatory requirements,” said Damien McDonald, Chief Executive Officer of LivaNova. “As we evaluated these changes along with those in the structural heart market, we determined it was no longer viable to continue to invest in our TMVR program. As a result, we will close our Caisson TMVR operations.”
  • September 2019: Abbott launched the first ever pivotal trial in the world to test new approach for repairing faulty tricuspid heart valves. The trial was aimed at evaluating the safety and effectiveness of the company’s TriClip transcatheter tricuspid valve repair system.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3327
  • Published Date: Nov 28, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing cardiovascular surgery and strong acquisition are the major factors driving the growth of the tricuspid insufficiency treatment market.

The market size of tricuspid insufficiency treatment is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2024-2036.

The major players in the market are Labcor Laboratorios Ltda., LivaNova, plc, Sorin S.p.A., Cyberonics, Inc., Hologic, Inc., Corcym UK Limited, Intuitive Surgical, Sonova Holding AG, and others.

The tricuspid regurgitation segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Europe region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying